PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs GSK |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.8 | 149.5% | -88% |
| AZN | AstraZeneca PLC | 0.21 | 12.7 | 61.0% | -79% |
| NVS | Novartis AG | 1.53 | 23.5 | 15.4% | +54% |
| MRK | Merck & Co., Inc. | 1.74 | 36.8 | 21.2% | +75% |
| BMY | Bristol-Myers Squibb Company | 3.37 | 17.6 | 5.2% | +239% |